You are here

Optimized Platforms for Proper Glycosylation and Sialylation of Recombinant Human Butyrylcholinesterase (rBChE)

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911QY-20-P-0034
Agency Tracking Number: C192-007-0016
Amount: $167,499.96
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD192-007
Solicitation Number: 19.2
Solicitation Year: 2019
Award Year: 2020
Award Start Date (Proposal Award Date): 2020-04-03
Award End Date (Contract End Date): 2020-09-03
Small Business Information
675 Arapeen Drive Suite 302
Salt Lake City, UT 84108
United States
DUNS: 179151188
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Paul Neilsen
 Director Research & Development
 (801) 588-0455
Business Contact
 Kelly Sauder
Phone: (801) 588-0455
Research Institution

Organophosphorus (OP) toxins and chemical warfare agents (CWA) are active nerve agents posing significant hazard for both soldiers and civilians. Butyrylcholinesterase (BChE) is a safe and effective bioscavenger that detoxifies OP and CWAs when injected either prophylactically or post-exposure; but a major technical problem has been producing a recombinant form of BChE with acceptable properties for human use, namely tetramerization and glycosylation for high activity and long-life in the blood. Our proposal capitalizes on over 30 years of research experience in protein engineering and glycosylation using baculovirus and novel insect hosts. First we will express BChE in an established glycoengineered baculovirus-insect system for production of recombinant proteins with fully humanized glycosylation patterns, including sialylation. Next, we will prepare a polyproline fusion protein with sequences known to induce stable tetramer formation. Finally, we combine these elements to evaluate the tetramerization and activity of BChE after affinity purification. We have assembled a unique set of technologies and experience to establish feasibility during this Phase I project. If successful, our proposal will create a system for commercializing active BChE as a biopharmaceutical treatment for neurotoxin exposure.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government